Meeting unmet needs in patients with sepsis: The role of drotrecogin alfa (activated)

American Journal of Critical Care

Volumn 12, Issue 2, 2003, Pages 94-97

  Morris, Peter E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

DRUG COST; ECONOMICS; EDITORIAL; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SEPSIS;

ANTI-INFECTIVE AGENTS; DRUG COSTS; HUMANS; PRACTICE GUIDELINES; PROTEIN C; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; SEPSIS;

EID: 0038283073     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2003.12.2.94     Document Type: Editorial

References (30)

1. Panati C. The Browser's Book of Beginnings: Origins of Everything Under, and Including, the Sun. New York, NY: Penguin Books; 1998.
2. Hardman JG, Limberd LE. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001.
3. The Leapfrog Group for Patient Safety. ICU physician staffing [fact sheet]. November 2000. Available at: http://www.leapfroggroup.org/FactSheets. htm. Accessed December 20, 2002.
4. Chan AL, Albertson TE. Team approach to the management of the patient with severe sepsis. In: Balk RA, ed. Advances in the Diagnosis and Management of the Patient With Severe Sepsis. London, England: Royal Society of Medicine; 2002:103-114.
5. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340:207-214.
6. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-1308.
7. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
8. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med. 1997;25:1095-1100.
9. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA. 1997;278:234-240.
10. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;274:968-974.
11. Wenzel RP, Edmond MB. Severe sepsis: national estimates. Crit Care Med. 2001;29:1472-1474.
12. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644-1655.
13. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you . . . Crit Care Med. 1997;25:372-374.
14. Opal SM, Cross AS. Clinical trials for severe sepsis: past failures, and future hopes. Infect Dis Clin North Am. 1999;13:285-297.
15. Rosenberg RD, Aird WC. Vascular bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
16. Krafte-Jacobs B, Brilli R. Increased circulating thrombomodulin in children with septic shock. Crit Care Med. 1998;26:933-938.
17. Moss M, Gillespie MK, Ackerson L, Moore FA, Moore EE, Parsons PE. Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome. Crit Care Med. 1996;24:1782-1786.
18. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345:408-416.
19. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 2001;120:915-922.
20. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost. 2001;86:51-56.
21. Smith D. 13th Annual Congress of the European Society of Intensive Care Medicine, Rome, Italy, 1-4 October 2000. Crit Care. 2000;4:347-351.
22. Chiron announces results of phase III study of tifacogin in severe sepsis [press release]. Emeryville, Calif: Chiron Corp; November 21, 2001. Available at: http://www.chiron.com/investor/news/index.htm. Accessed December 6, 2002.
23. Esmon C. The protein C pathway. Crit Care Med. 2000;28(9 suppl):S44-S48.
24. Ely EW, Kleinpell RM, Goyette RE. Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses. Am J Crit Care. 2003;12:120-135.
25. Burrows R, Crippen D, Dellinger RP, Kelly DF, Streat S, Whetstine LM. Ethics roundtable: using new, expensive drugs. Crit Care. 2002;6:473-478.
26. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002;347:993-1000.
27. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31:1-11.
28. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10:321-330.
29. Owens DK, Sanders GD, Harris RA, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12.
30. Sollet JP, Garber GE. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy. Am J Surg. 2002;184:S11-S18.